Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I–II non-small-cell lung cancer

Bonfili, Pierluigi; Staso, Mario Di; Gravina, Giovanni Luca; Franzese, Pietro; Buonopane, Sergio; Soldà, Francesca; Festuccia, Claudio; Tombolini, Vincenzo

doi:10.1016/j.lungcan.2009.03.023

Cited by 22 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 2-year OS of 54.3%, 2-year PFS of 61.1%, 2-year LC of 74.6%, and 2-year LRFS of 61.9% were achieved; this outcome was comparable with results from previous HFRT reports (2-year OS of 50-60%, 2-year LC of 63-76%), but PFS was superior to those reported in previous studies (2-year PFS of 38-40%) [10-14]. Local failure was the predominant pattern, as in previous studies of radical radiotherapy in early stage NSCLC [3,11,17].…”

Section: Discussionsupporting

confidence: 84%

“…Hypofractionated radiotherapy (HFRT) using 3D-CRT can be considered as the second policy in clinics and patients ineligible for SABR. Some studies of HFRT using various radiation dose schedules resulted in improved outcomes beyond those achieved with conventionally fractionated radiotherapy [10-14]. Thus, the purpose of the present study was to assess the clinical outcomes of HFRT for medically inoperable patients with early stage NSCLC and to evaluate prognostic factors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer

Lee

Kim

et al. 2013

Radiat Oncol J

View full text Add to dashboard Cite

PurposeThe purpose of this study was to assess the clinical outcomes of hypofractionated radiotherapy (HFRT) with three-dimensional conformal technique for medically inoperable patients with early stage non-small-cell lung cancer (NSCLC) and to evaluate prognostic factors.Materials and MethodsWe performed a retrospective review of 26 patients who underwent HFRT for early stage NSCLC between September 2005 and August 2011. Only clinical stage T1-3N0 was included. The median RT dose was 70 Gy (range, 60 to 72 Gy) and the median biologically equivalent dose (BED) was 94.5 Gy (range, 78.0 to 100.8 Gy). In 84.6% of patients, 4 Gy per fraction was used. Neoadjuvant chemotherapy with paclitaxel and cisplatin was given to 2 of 26 patients.ResultsThe median follow-up time for surviving patients was 21 months (range, 13 to 49 months). The overall response rate was 53.9%, and the initial local control rate was 100%. The median survival duration was 27.8 months. Rates of 2-year overall survival, progression-free survival (PFS), local control (LC), and locoregional-free survival (LRFS) were 54.3%, 61.1%, 74.6%, and 61.9%, respectively. Multivariate analysis showed that BED (>90 vs. ≤90 Gy) was an independent prognostic factor influencing PFS, LC, and LRFS. Severe toxicities over grade 3 were not observed.ConclusionRadical HFRT can yield satisfactory disease control with acceptable rates of toxicities in medically inoperable patients with early stage NSCLC. HFRT is a viable alternative for clinics and patients ineligible for stereotactic ablative radiotherapy. BED over 90 Gy and 4 Gy per fraction might be appropriate for HFRT.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Hypofractionated three-dimensional conformal radiotherapy for medically inoperable early stage non-small-cell lung cancer

Lee

Kim

et al. 2013

Radiat Oncol J

View full text Add to dashboard Cite

show abstract

“…Another study presenting results about toxicity in 51 patients older than 65 years shows no augmentation of the toxicity in these patients in function with age, but survival was significantly correlated with performance status and importance of comorbidities (Fiorica et al, 2010). Retrospective case series of older patients treated with curative radiation alone have demonstrated a median survival of up to 37 months for stage I-II and 8 months pour stage III (Bonfili et al, 2009;Lonardi et al, 2000;San José et al, 2006& Tombolini et al, 2000. It is recommended to provide elderly patients with advanced lung cancer disease in good general condition radiotherapy combined with chemotherapy.…”

Section: Radiotherapymentioning

confidence: 99%

Lung Cancer in Elderly

Dagnault¹,

Archambault²

2012

Topics in Cancer Survivorship

View full text Add to dashboard Cite

“…n Stage Median age (range) Radiotherapy dose/fractionation Survival Gd 3+ acute oesophagitis/pneumonitis Gauden and Tripcony [18] 162 I 50 Gy (2.5 Gy per fraction) minimum tumour dose 34% at 5 years Not recorded Furuta et al [15] 32 I-II 79 (75)(76)(77)(78)(79)(80)(81)(82)(83)(84)(85)(86) >60 Gy (2.0 Gy per fraction) 40% at 2 years 0 Bonfili et al [14] 36 I-II 77 60 Gy (3.0 Gy per fraction) 55.6% at 2 years 0 San Jose et al [12] 33 I-II 75 Median 70 Gy (2.0 Gy per fraction) 50% at 3 years 6% Yu et al [27] 80 I-II 76 (70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81)(82)(83)(84) 66.6 Gy (1.8 Gy per fraction) 55.7% at 2 years 5.1% Pergolizzi et al [26] 40 IIIa 77 (75)(76)(77)(78)(79)(80)(81)(82)(83) Median 60 Gy (2.0 Gy per fraction) 18% at 3 years 5% Lonardi et al [11...…”

Section: Referencementioning

confidence: 99%

“…Retrospective case series of elderly patients receiving radical external beam radiotherapy (EBRT) alone for NSCLC have demonstrated a median survival of up to 37 months for stage I-II disease and 8 months for stage III disease [11][12][13][14][15]. Several retrospective series have compared outcomes for elderly and younger patients with NSCLC treated with EBRT and shown that age is not a negative prognostic factor [16][17][18][19][20][21].…”

Section: Referencementioning

confidence: 99%